Factor Eight Inhibitor Bypassing Agent (FEIBA) for Reversal of Target-Specific Oral Anticoagulants in Life-Threatening Intracranial Bleeding

Gordon Mao, Lauren King, Sarah Young, Richard Kaplan

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction As increasing number of patients present to emergency departments with life threatening hemorrhages, particularly intracranial hemorrhage on anticoagulation physicians must be cognizant of the limitations of the available reversal options. Based upon the available literature, our institution formulated a reversal algorithm for patients with life-threatening bleeding on factor Xa inhibitors by administering factor eight inhibitor bypassing agent (FEIBA) 20 units/kg. Methods A retrospective chart review was performed to include all patients who received FEIBA per institutional protocol. This case series excluded patients who received FEIBA for reversal of dabigatran. Pre and post FEIBA CT scans were compared for changes. Finally, patients were stratified by estimated mortality rates calculated based on pre-intervention characteristics via published risk models. Results Thirteen patients were initially included in this study yet two patients were excluded because they were on dabigatran. Fifty-five percent of patients demonstrated stable ICH on CT scan after FEIBA administration while thirty-six percent showed worsening scans. Two patients developed thrombotic events after FEIBA administration. Discussion FEIBA is a treatment option in patients on a TSOA with acute intracranial hemorrhage with evidence of at least partial pharmacologic reversal of their anticoagulation status. There does not appear to be any major risk of thromboembolic complications associated with FEIBA. Much larger study sizes will be necessary to establish statically significant clinical efficacy for FEIBA use in this patient population. Why Should an Emergency Physician Be Aware of This? Emergency medicine physicians are first-line caretakers for patients with life threatening intracranial hemorrhages whether spontaneous or traumatic. FEIBA is a potentially safe option to reverse TSOA in this patient population.

Original languageEnglish (US)
Pages (from-to)731-737
Number of pages7
JournalJournal of Emergency Medicine
Volume52
Issue number5
DOIs
StatePublished - May 2017
Externally publishedYes

Keywords

  • anti-xa inhibitor
  • anticoagulation
  • apixaban
  • dabigatran
  • FEIBA
  • intracranial hemorrhage
  • life-threatening bleeding
  • reversal
  • rivaroxaban
  • target-specific oral anticoagulants

ASJC Scopus subject areas

  • Emergency Medicine

Fingerprint Dive into the research topics of 'Factor Eight Inhibitor Bypassing Agent (FEIBA) for Reversal of Target-Specific Oral Anticoagulants in Life-Threatening Intracranial Bleeding'. Together they form a unique fingerprint.

Cite this